{"id":6355,"date":"2023-12-06T04:40:13","date_gmt":"2023-12-06T04:40:13","guid":{"rendered":"https:\/\/healthnewscentral.com\/?p=6355"},"modified":"2023-12-06T04:40:13","modified_gmt":"2023-12-06T04:40:13","slug":"oxford-makes-huge-advance-in-new-malaria-vaccine-to-protect-children-from-deadly-disease","status":"publish","type":"post","link":"https:\/\/healthnewscentral.com\/oxford-makes-huge-advance-in-new-malaria-vaccine-to-protect-children-from-deadly-disease\/","title":{"rendered":"Oxford Makes \u2018Huge Advance\u2019 In New Malaria Vaccine To Protect Children From Deadly Disease"},"content":{"rendered":"
\"\"
University of Oxford<\/figcaption><\/figure>\n

Oxford\u2019s latest malaria vaccine, R21, has demonstrated not only its efficacy in preventing malaria in children but also boasts a more accessible production process and a lower price tag, promising increased protection for numerous African countries.<\/p>\n

The World Health Organization (WHO)<\/a> recently endorsed the R21\/Matrix-M vaccine<\/a>, marking the second malaria vaccine recommendation in two years, following the RTS,S\/AS01 vaccine in 2021.<\/p>\n

Both vaccines have exhibited safety and effectiveness in shielding children from malaria a lethal disease that claimed the lives of 619,000 individuals in 2021 alone. The widespread implementation of these vaccines is anticipated to make a substantial public health impact in the African Region, where malaria is predominantly transmitted by mosquitoes.<\/p>\n

Despite a high demand for malaria vaccines, the availability of the RTS,S vaccine<\/a> is constrained. The introduction of the R21 vaccine is poised to address this supply limitation, potentially benefitting all children residing in malaria-endemic areas.<\/p>\n

\u201cAs a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two. Demand for the RTS,S vaccine far exceeds supply, so this second vaccine is a vital additional tool to protect more children faster, and to bring us closer to our vision of a malaria-free future,\u201d<\/strong><\/em> said Dr. Tedros Adhanom Ghebreyesus<\/a>, WHO\u2019s Director-General.<\/p>\n

The WHO Regional Director for Africa underscores the potential of the second vaccine to bridge the supply gap, safeguarding hundreds of thousands of young lives across the continent.<\/p>\n

Finding from the ongoing R21 vaccine clinical trial and related studies highlight several key aspects:<\/strong><\/p>\n